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Abstract: Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack
of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual
disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and
side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability
and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate
lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure
homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex
vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand
rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an
average size of 90 nm, monomodal population, positive surface charge and a high molecular weight
protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and
any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the
ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular
irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as
suitable approach in the treatment of DED.
Keywords: lactoferrin; liposomes; dry eye disease; ocular anti-inflammatory; drug delivery
1. Introduction
Dry eye disease (DED) or keratoconjunctivitis sicca is considered a chronic multifacto-
rial pathology of the ocular surface characterized by a loss of homeostasis of the tear film,
associated with characteristic ocular symptoms, such as tear film instability and hyperos-
molarity, ocular surface inflammation and damage. Moreover, neurosensory abnormalities
play etiological roles, according to the TFOS DEWS II [1].
DED is one of the most frequent ocular surface conditions, affecting millions of patients
globally, with a prevalence ranging from 5 to 50% [2,3]. Numerous risk factors are identified,
including advanced age, female gender, Sjögren syndrome, androgen deficiency, several
medications such as antihistamines, antidepressants, anxiolytics, or oral contraceptives,
thyroid disease, menopause and smoking, among others [4]. Moreover, the continuous use
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of contact lenses, certain environmental conditions as elevated pollution or low humidity,
and the excessive smartphone and computer use has led to an increase in DED incidence
especially among the younger population [4].
This osmotic and cellular stress at the ocular surface leads to irritation, ocular surface
inflammation, soreness, blurred vision, and visual disturbance, resulting in a considerable
decline in quality of life [3]. The elevated tear osmolarity, oxidative and mechanical stress-
associated trigger a pro-inflammatory environment [5]. It is characterized by a broad
release of pro-inflammatory mediators, cytokines, chemokines, and immune cells, leading
to the extracellular matrix degradation and disruption of tight junctions between corneal
epithelial cells. These conditions damage the ocular surface and favour inflammatory cell
recruitment [6,7]. Thus, generating a self-inflammatory feedback loop that affects ocular
function and integrity [4].
Topical administration is the preferred route to treat DED because it is painless and
easy to handle. Artificial tears in the form of eyedrops, gel or ointment are used to lubricate
dry eyes maintaining moisture of the eye’s surface and often constitute the first line of
therapy. They instantly relieve symptoms by lowering osmolarity and diluting inflamma-
tory markers. However, artificial tears have no anti-inflammatory properties and do not
deal with the fundamental pathogenesis of the disease [4]. Moreover, usual treatments for
ocular inflammation comprises corticosteroids and non-steroidal anti-inflammatory drugs
(NSAIDs), but its prolonged use involves severe side effects [8–10].
To overcome these drawbacks, lactoferrin (LF), an iron-binding glycoprotein with anti-
inflammatory, antiviral, antibacterial, antifungal, antiparasitic, and immunomodulatory
properties, has been investigated to address various ocular disorders [11–14].
LF has two highly homologous lobes with stable and reversible iron-binding capacity.
LF is secreted by neutrophils and exocrine glands and it is found in colostrum and milk,
tears, saliva, or gastrointestinal secretions [15]. At ocular level, LF amount is around
20–30% in basal and reflex tears and is also present in vitreous humour and a variety of
ocular tissues, such as cornea, iris, and retinal pigment epithelium [16,17]. Moreover, recent
studies have confirmed that the concentration of LF in tear fluids is considerably lower in
patients with DED [18].
Most of the in vitro and in vivo studies have been assayed using bovine LF (bLF)
since presents high sequence homology and has analogous functions to human LF [19].
bLF is generally recognized as safe substance (GRAS) by the Food and Drug Administra-
tion (FDA) and the European Food Safety Authority (EFSA) [19,20]. bLF is internalized
by corneal epithelial cells and exerts its anti-inflammatory activity by attenuating the
nuclear transcription factor kappa B (NF-κB)-induced transcription of genes for several
inflammatory mediators [19,21–23].
Furthermore, reactive oxygen species (ROS) also play a major role in inflammatory
processes. It has been reported that redox reactions are triggered by the presence of free
iron, as it can easily accept or donate electrons, favouring the formation of ROS [18]. bLF
can scavenge oxygen free radicals and hydroxyl, presenting a potential approach to treat
DED [24,25].
However, one of the major challenges of ocular treatment, is the fast elimination
via conjunctiva and nasolacrimal duct. It results in a pre-corneal drug half-life of 1–3
min and the need for frequent administrations [26]. In consideration of that, during the
last years, drug administration using nanotechnological carriers for controlled release
has attracted great interest, owing to improved stability, permeability, and bioavailability,
offering advantages over traditional pharmaceutical forms [27,28].
Liposomes, since discovery by Bangham [29], have been widely used as delivery
system for therapeutic and diagnostic compounds such as drugs, imaging agents, genes,
or proteins [30]. Liposomes enhance the active corneal permeability due to their ability to
come in close contact with cornea and conjunctiva as well as increase the extent of corneal
uptake by prolonging the corneal contact time [31].
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Therefore, bLF encapsulation into biocompatible and biodegradable liposomes has
been carried out to overcome its compromised stability and increase therapeutic activity
and half-life in the ocular surface, granting its prolonged release [31,32].
Moreover, one of the most utilised viscosity-building macromolecules in ocular deliv-
ery devices is hyaluronic acid (HA), an anionic polysaccharide with ocular mucomimetic
properties, that exhibits the capacity of prolonging the precorneal residence time and
reducing surface desiccation [3,33].
Therefore, the aim of this study was the development of a nanostructured drug
delivery system based on HA-coated bLF-loaded liposomes for the treatment of DED. This
study has focused on the incorporation of a high molecular weight protein within a lipidic
nanocarrier. Likewise, different in vitro and in vivo studies have been carried out to assess
their biocompatibility, capability to reverse DED symptoms, and anti-inflammatory efficacy.
Moreover, achievement of sustained drug release and corneal permeability is essential for
improving the pharmacokinetic and pharmacodynamic profile of bLF.
2. Materials and Methods
2.1. Materials
bLF was purchased from Azienda Chimica e Farmaceutica (Fiorenzuola d’Arda,
Italy); fat-free soybean phospholipids with 70% phosphatidylcholine (lipoid S75) from
Lipoid Gmbh (Ludwigshafen am Rhein, Germany); cholesterol and polysorbate 80 were
purchased from Sigma Aldrich (Madrid, Spain); and Sodium hyaluronate was kindly
donated by Bloomage Freda Biopharm (Jinan, China). Water filtered through a Millipore®
MilliQ system was used for all the experiments and all the other reagents used were of
analytical grade.
2.2. Lactoferrin Loaded Liposomes Production
bLF loaded liposomes (bLF-LIP) were produced using lipid film hydration method [34].
Briefly, the oil phase was formed dissolving a predetermined amount of lipids (lipoid S75)
and cholesterol in 2 mL of ethanol (0.002% tocopherol). Aqueous phase was obtained by
dissolving bLF (20 mg ×mL−1) and polysorbate 80 (P80) (3 mg·mL−1) in 10 mL of deion-
ized water. The lipid film was achieved by removing the organic solvent of the oil phase,
under reduced pressure, using the rotary evaporation method (Rotavapor® R-210/215
Buchi, Flawil, Switzerland). To ensure complete solvent evaporation, the obtained film
was subjected to a nitrogen flow for 10 min. Then, the aqueous phase was added to the
lipid film and the mixture was homogenized using an ultrasonic bath (Transsonic Digitals,
Elma Schmidbauer GmbH, Singen, Germany). Subsequently, the liposomes undergo a
high-pressure homogenization process at 800 mbar at room temperature (2 cycles) by
Stansted-pressure cell homogeniser-FPG12800 (Stansted Fluid Power, Harlow, UK). Finally,
sodium hyaluronate was added under magnetic stirring to obtain a hyaluronic acid (HA)
concentration of 0.1 mg·mL−1.
2.3. Optimization of Lactoferrin Loaded Liposomes
A factorial 23 design matrix was employed to obtain the optimal formulation us-
ing StatGraphics Centurion XVI.I. This design was established to evaluate the effects of
the independents variables (bLF, lipoid S75 and P80 concentrations) on the dependent
parameters (average particle size (Zav), polydispersity index (PI), zeta potential (ZP) and en-
capsulation efficiency (EE)) [35]. Each factor was examined at two levels and the responses
were modelled through the first-order equation.
2.4. Physicochemical Characterization
Physicochemical parameters such as Zav and PI or ZP were acquired by dynamic light
scattering (DLS) and electrophoresis laser doppler, respectively, using a ZetaSizer NanoZS
(Malvern Instruments, Malvern, UK). Samples were diluted (1:20) and measurements were
carried out by triplicate at 25 ◦C [36].
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EE was determined indirectly by quantifying the non-loaded bLF in the dispersion
medium. bLF-LIP were ultracentrifugated at 4 ◦C and 45000 rpm for 60 min and the
non-entrapped drug was isolated (Optima® Beckman Coulter, Brea, CA, USA). Then,
supernatant was used to evaluate the EE according to the following equation [37]:
EE(%) =
Total amount of bLF− Free amount of bLF
Total amount of bLF
× 100 (1)
The amount of the bLF in the aqueous phase was quantified by a reverse-phase high-
performance liquid chromatography (RP-HPLC) method described elsewhere [38]. The
methodology was validated in accordance with the international guidelines (EMEA, 2011),
involving the evaluation of linearity, sensitivity, accuracy, and precision. Concisely, samples
were quantified employing HPLC Waters 2695 separation module (Waters, Milford, MA,
USA) and a Europa® Protein 300 C8 column (5 µm, 250 × 4.6 mm) (Teknokroma Analítica,
Barcelona, Spain). Mobile phase was constituted by a water phase containing 0.1% trifluoro
acetic acid (TFA) and an organic phase consisting on acetonitrile/water/TFA (95:5:0.1),
applying a gradient (from 95% to 25% of water phase and back in 8 min, keeping this ratio
up to 25 min) at 0.75 mL·min−1. Concentrations ranged from 0.1 to 1 mg·mL−1 were used
in calibration curve. A diode array detector Waters® 2996 (Waters, Milford, MA, USA)
at a wavelength of 219 nm was utilized to identify the bLF and data were handled using
Empower 3® Software.
2.5. Morphological Characterization and Interaction Studies of Optimized Liposomes
The morphological evaluation of bLF-LIP was done using a Tecnai® G2 F20 TWIN
cryogenic transmission electron microscopy (Cryo-TEM) (FEI Company, Hillsboro, OR,
USA). Interaction studies were carried out through Differential Scanning Calorimetry
(DSC). Thermograms were acquired on a Mettler TA 4000 system (Mettler, Greifensee,
Switzerland) equipped with a DSC-25 cell. Samples were weighted in perforated alu-
minium pans (Mettler M3 Microbalance, Mettler, Greifensee, Switzerland) and heated
under nitrogen flow at rate of 10 ◦C/min. An empty pan with similar attributes was
utilized as reference [26].
2.6. Stability Studies
The stability of bLF-LIP stored at 4 and 25 ◦C was studied analysing light backscat-
tering (BS) using Turbiscan® Lab (Formulaction, Toulouse, France). Twenty millilitres of
sample were introduced into a glass measurement cell. The light source was a pulsed near
infrared light source (λ = 880 nm) and it was detected by a BS detector at an angle of 45◦
from the incident beam. BS data were obtained at 1, 15, 30 and 60 days for 24 h at periods
of 1 h. Likewise, measures of Zav, PI, ZP, and EE were assayed.
2.7. Biopharmaceutical Behaviour
Direct dialysis bag technique was applied to examine the in vitro release profile
due to the hydrophilicity of bLF [39]. bLF-LIP were placed in 1 mL dialysis bags (Float-
A-Lyzer® dialysis device, 1000 kDa) (Repligen Corporation, Waltham, MA, USA) and
phosphate buffer saline (PBS) 0.1 M buffer solution (pH 7.4) was employed as release
medium and maintained under magnetic stirring at 37 ◦C. At various time intervals, 1 mL
of release medium was removed and replaced with fresh buffer solution. RP-HPLC method
previously described was used to analyse and data were adjusted to the most frequent
pharmacokinetic models [40].
The ex vivo bLF permeation study from bLF-LIP was carried out using isolated
corneas from New Zealand rabbits (2.5 kg males), according to the Ethics Committee of
Animal Experimentation from the University of Barcelona (CEEA-UB), using a method
described elsewhere [26]. Briefly, corneas were placed in a Franz-type cell between donor
and receptor compartments. The receptor compartment was filled with PBS at 32 ◦C, under
magnetic stirring. At pre-selected times, 300 µL of sample were withdrawn and replaced
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by PBS. Samples were directly quantified by RP-HPLC [11,41]. Tests were carried out by
triplicate and values were registered as the mean ± SD.
2.8. Cytotoxicity
Human corneal epithelial cells (HCE-2) (LGC Standards, Barcelona, Spain) were used
to perform in vitro MTT cytotoxicity assay, previously described [42]. To elucidate the
possible cytotoxicity of the formulation, cells were exposed to bLF-LIP and free bLF at
different drug concentrations (0.2–2 mg·mL−1) for 24 h of incubation. The absorbance was
read at λ = 560 nm by an automatic Modulus® Microplate Photometer (Turner BioSys-
tems, Sunnyvale, CA, USA). Viability was expressed as percentage of negative control
(untreated cells).
2.9. Ocular Tolerance
To assess ocular tolerance, in vitro HET-CAM test was carried out to guarantee that
bLF-LIP was non-irritating after topical administration [43]. Irritation, coagulation, and
haemorrhage phenomena in the chorioallantoic membrane of a fertilized chicken egg were
evaluated by applying 300 µL of samples. The effects were checked during the first 5 min
after the application. Test was performed according to the guidelines of ICCVAM (The
Interagency Coordinating Committee on the Validation of Alternative Methods). Eggs
(purchased from the farm G.A.L.L.S.A, Tarragona, Spain) were kept at 12 ± 1 ◦C for at
least 24 h before putting them in the incubator with monitored temperature (37.8 ◦C) and
humidity (50–60%) during the incubation days. At day 9 of incubation, 3 eggs were used
for each group (free bLF, bLF-LIP, positive control (NaOH 0.1 M) and negative control
(0.9% NaCl). Ocular irritation index (OII) was determined by the sum of the scores of each











where H, V, and C are times (s) up to the start of haemorrhage (H), vasoconstriction (V),
and coagulation (C), respectively. The formulations were categorized according to the
following classification: OII ≤ 0.9 non-irritating; 0.9 < OII ≤ 4.9 weakly irritating; 4.9 < OII
≤ 8.9 moderately irritating; 8.9 < OII ≤ 21 irritating [43,44].
To confirm the results acquired from the HEM-CAM test, in vivo Draize test was
carried out to evaluate primary ocular irritation [26]. New Zealand male albino rabbits
of 2.0–2.5 kg were maintained under monitored ambient conditions with food and water
ad libitum. For the experiment, 50 µL of bLF-LIP suspension were applied in the ocular
conjunctival sac followed by a slight massage (n = 3/group). The appearance of irritation
signs was evaluated at the time of instillation and following 1 h. If necessary, evaluation
was also carried out at predefined intervals: 24 h, 48 h, 72 h, and 7 days. Draize test
score was established by examining the ocular anterior segment and alterations in the
structures of the cornea (turbidity or opacity), iris, and conjunctiva (congestion, chemosis,
and swelling) (for detailed punctuation see Table A1 of Appendix A).
2.10. Induction and Treatment of Dry Eye
Induction of moderate dry eye was performed in male New Zealand albino rabbits
(2.5 kg). The animals were treated for two weeks with two drops per day of 0.1% benza-
lkonium chloride in the right eye. Afterwards, the tear level was evaluated throughout
Schirmer’s test and the animals were treated for 5 days, either with bLF- LIP or with NaCl
0.9% (positive controls) [45].
Measurement of aqueous tear secretion was carried out using tear strips of Care
Group® (Gujrat, India). General anaesthesia was induced to the rabbits using intramuscular
ketamine/xylazine (35/5 mg/kg). Subsequently, 0.5% proparacaine (local anaesthetic) was
administered topically. The lower eyelid was pulled down slightly and placed the test
paper strip on the palpebral conjunctival vesica, which is near the junction of the middle
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and outer third of the lower lid. The soaked length (in millimeters) of the paper strip was
read 5 min later. The procedure was performed by triplicate [45].
2.11. Anti-Inflammatory Efficacy Assays
In vitro proinflammatory cytokines determination was assessed to evaluate the anti-
inflammatory activity of the bLF-LIP and free bLF in HCE-2 cells. Samples were added
to the culture medium at 2 mg·mL−1 of bLF and inflammation was induced with LPS
(1 µg·mL−1). Cells stimulated only with LPS were set as a positive control and untreated
cells as a negative control. After 24 h incubation, supernatants were collected and pro-
inflammatory cytokine levels (IL-8 and TNF-α) were quantified using the enzyme-linked
immunosorbent assay (ELISA) according to manufacturer’s instructions.
In vivo anti-inflammatory effectiveness was carried out throughout the evaluation test
for the inflammation prevention ability and the anti-inflammatory efficacy. Assays were
carried out using New Zealand male albino rabbits (n = 3/group), described previously.
The activity of bLF-LIP in comparison with free bLF and NaCl 0.9% (control group) was
measured. The inflammation prevention study consisted of the ocular application of 50 µL
of each formulation. After 30 min of exposure, an inflammatory stimulus, 50 µL of 0.5%
sodium arachidonate (SA) dissolved in PBS, was instilled in the right eye and the left
eye was used as a control. In the anti-inflammatory treatment study, the inflammatory
stimulus was applied 30 min before than the application of each formulation tested. The
evaluation of prevention and treatment of each formulation were carried out from the first
application up to 210 min, according to the Draize modified test scoring system (Table A1
of Appendix A) [26].
2.12. Statistical Analysis
Two-way ANOVA followed by Tukey post hoc test was performed for multi-group
comparison. Student’s t-test was used for two-group comparisons. All the data are
presented as the mean ± S.D. Statistical significance was set at p < 0.05 by using GraphPad
Prism 8.4.3. ImageJ was used to analyse images.
3. Results and Discussion
3.1. Optimization Study
Aiming to achieve the optimal formulation, the effect of independent variables such
as concentrations of bLF, lipoid S75 and P80 on the physicochemical properties of the
liposomes was evaluated by 23 factorial design. Table 1 shows the results obtained in the
optimization study and the corresponding surface responses are showed in Figure 1.
Table 1. Values of the 23+ star central composite rotatable factorial design, parameters and measured responses. Results
presented as mean ± standard deviation.
Independent Variables Dependent Variables
cP80 cbLF cLipoid-S75 Zav PI ZP EE
(mg·mL−1) (mg·mL−1) (mg·mL−1) (nm) (mV) (%)
1 −1 2.0 −1 10.0 −1 30.0 253.6 ± 2.2 0.121 ± 0.024 21.9 ± 0.6 49.2 ± 0.9
2 1 3.0 −1 10.0 −1 30.0 378.2 ± 1.4 0.317 ± 0.064 16.3 ± 0.3 40.6 ± 0.3
3 −1 2.0 1 20.0 −1 30.0 160.0 ± 3.9 0.179 ± 0.021 22.9 ± 0.2 55.4 ± 1.7
4 1 3.0 1 20.0 −1 30.0 85.0 ± 2.4 0.165 ± 0.033 22.7 ± 0.3 50.0 ± 2.5
5 −1 2.0 −1 10.0 1 60.0 471.7 ± 2.3 0.383 ± 0.046 24.3 ± 1.9 39.6 ± 4.0
6 1 3.0 −1 10.0 1 60.0 133.7 ± 1.4 0.292 ± 0.036 25.4 ± 0.6 33.1 ± 1.5
7 −1 2.0 1 20.0 1 60.0 602.8 ± 6.2 0.282 ± 0.016 26.0 ± 1.2 35.3 ± 0.4
8 1 3.0 1 20.0 1 60.0 242.1 ± 2.3 0.484 ± 0.031 26.2 ± 0.3 37.4 ± 0.3
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Figure 1. (a) Zav, (b) PI, and (c) EE (%) surface response at a fixed P80 concentration (3 mg·mL−1).
(d) ZP surface response at a lipid concentration (30 mg·mL−1).
Concerning Zav, PI, and EE, lower lipids concentrations (30 mg·mL−1) and higher
protein concentrations (20 mg·mL−1) favoured smaller particle size, lower PI values, and
greater drug encapsulation. Regarding EE and ZP, the most influential variable was lipoid
S75 concentration. bLF-LIP obtained had an average size of 85 nm, + 23 mV of ZP, and PI
around 0.165, characteristic of a monomodal system, so they are suitable for ocular adminis-
tration [46]. The PI is a measure of size distribution, agreeing with the literature, liposomal
formulation is considered to be heterogeneous if the value is > 0.3 [47]. Cationic liposome
formulation improves ocular surface adherence since ocular mucosa depicts slightly nega-
tive charge over its isoelectric point, thus increasing ocular bioavailability and prevent tear
washout, prolonging corneal residence time [48]. P80 surfactant concentrations showed a
slight effect on ZP, being inversely proportional. Increasing the concentration of surfactant
resulted in significant particle size reduction. Results are in accordance with those obtained
by other authors [49,50]. During the last years, the use of surfactants has been researched
for the application in liposomal formulations. P80 is a biodegradable, non-ionic surfactant
with great emulsifying properties, generally recommended as safe (GRAS) excipient with
established safety profile, without causing ocular irritation [51]. It has reported to be well
tolerated in ocular administration up to concentrations of 10% [52]. According to FDA
GRAS list, the maximum allowable limit for its use in ophthalmic emulsions is 4% w/w,
thus, in the factorial design we have chosen concentration in the range of 0.02–0.03% w/w
to minimize adverse effects [53]. The addition of P80 decreases the interfacial tension and
form smaller emulsion droplets by stabilizing oil/water interface [54].
From the factorial design outcomes, an optimized formulation (F4) was selected.
As it can be noted in Table 1, the optimized bLF concentration was 20.00 mg·mL−1,
30.00 mg·mL−1 of lipoid S75 and 3.00 mg·mL−1 of surfactant. The morphometry and
surface charge (Zav, PI and ZP) were established by photon correlation spectroscopy.
Final optimized formulation, obtained by adding hyaluronic acid (HA) 0.1 mg·mL−1
to formulation 4 of factorial design, retained suitable physicochemical properties for ocular
administration (Table 2). Zav and PI of the HA coated liposomes increased slightly after
HA addition, whereas ZP became less positive. This is due to the fact that HA molecules
possess a negatively charged carboxylic acid groups in their chemical structure which are
able to interact with cationic liposomes (F4) by electrostatic forces. This caused a decrease
in ZP and also led to a tiny increase in Zav and PI [55].
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Table 2. Physicochemical parameters of bLF-LIP after adding HA.
Zav PI ZP EE
(nm) (mV) (%)
90.5 ± 0.6 0.201 ± 0.070 20.5 ± 0.4 50.0 ± 3.0
Values are expressed as mean ± standard deviation.
3.2. Morphological Characterization
The addition of HA produced a slight increase in average size and PI and a slight ZP
reduction, maintaining a strongly positive potential that favours the stability of the system
through repulsion by electrostatic forces between particles [56]. Optimized bLF-LIP were
characterized morphologically by imaging using cryo-TEM (Figure 2a). Images revealed
a spherical and homogenous shape of bLF-LIP, without aggregation events and average
particle dispersion similar to the obtained by DLS. According to other authors, the addition
of P80 surfactant could contribute to the morphology improvement [54].
3.3. Interaction Studies
A factor that considerably influences the pharmacokinetics of the active substance is
the physical state of the drug inside the nanosystem. DSC study was carried out to deter-
mine the physical state of bLF and the components of the formulation (Figure 2b). The bLF
thermogram presents a severe endothermic accident related to its fusion, with a maximum
temperature (Tmax) of 170.41 ◦C which was not found in bLF-LIP. The cholesterol melting
peak (Tmax 150 ◦C) was also missing. The HA thermogram showed a wide and slight
endothermic event around 100 ◦C, which appeared smoothed in the bLF-LIP thermogram
compared with the lipoid S75 one, may be due to the melting of the polymer [57]. Typically,
HA presents an exothermic peak at around 240 ◦C, attributed to the degradation of the
polysaccharide. However, it is not observed since it is out of the temperature range, being
not relevant to the study [57,58]. Likewise, the lipoid S75 thermogram did not exhibit any
thermal events in the range, as a consequence of its low melting point [59]. Empty lipo-
somes showed a similar thermogram to bLF-LIP. Data suggest the adequate incorporation
of the formulation components within the bLF-LIP structure.
Figure 2. (a) Cryo-TEM image of bLF-LIP. (b) DSC thermograms of bLF-LIP.
3.4. Stability of Lactoferrin Loaded Liposomes
The BS profile of bLF-LIP was analysed over 60 days (Figure 3). This technique
identifies the different destabilization phenomena of the colloidal suspension such as
creaming, sedimentation and flocculation or coalescence [60]. The optimized formulation
was stored at 4 and 25 ◦C. BS profile did not show any process of destabilization or
migration of particles through the time or fluctuations greater than 5%, which indicates that
bLF-LIP remain stable stored at both temperatures. This technique allows predicting the
instability courses of liposomes earlier than detected by other methods [28]. Furthermore,
several authors have reported that liposomal particle size bellow 90 nm allows for better
Pharmaceutics 2021, 13, 1698 9 of 19
stability of the colloidal dispersion because gravitational phase partition is avoided by
Brownian motion [56]. Moreover, the high value of ZP, over +20 mV, avoids electrostatic
interaction between particles and the consequent phenomena of instability [61].
Figure 3. Backscattering profiles of bLF-LIP stored at: (a) 4 ◦C and (b) 25 ◦C.
3.5. Biopharmaceutical Behaviour of bLF-LIP
The in vitro release of bLF from bLF-LIP and free bLF exhibited a controlled and
prolonged release of bLF from nanosystems. The release from liposomes arises as a function
of physical and chemical processes that compromise membrane stability carrying out to a
few or complete leakage of the liposomal content [62]. Drug release is highly dependent
on the composition of the liposomal formulation, including amount of cholesterol, charge,
side chains or acyl chain length; and also on the pharmacokinetic properties of the drug
itself [62]. Free bLF showed an earlier release, reaching 98% after 24 h, adjusted to hyperbola
equation release profile (AIC = 90.60, r2 = 0.96), characterized by a rapid release followed
by a prolonged release [63]. However, bLF-LIP formulation exhibited a more sustained
release. Characterized by a faster bLF release stage, during the first 24 h, up to 50.53%,
and afterward, the release speed of bLF-LIP decreased significantly, leading to a prolonged
release up to 71.44% after 72 h, without reaching a plateau (Figure 4a).
The non-linear regression models such as Higuchi or Korsmeyer–Peppas are the two
most utilized mathematical models to interpret non-linear diffusion profiles [64]. This
biphasic release profile was probably caused by the drug diffusion through the bilayer and
HA coating [65]. The Korsmeyer–Peppas release kinetics was the most accurate model to
fit the experimental data, showing a minimum Akaike Information Criterion (AIC) value
and a maximum r2 value (AIC = 67.83, r2= 0.98). Data were adjusted to the most common
kinetic models to obtain the best fit for bLF release (Table 3).
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Table 3. Parameters for kinetic models of bLF-NPs and free bLF solution.
Models
bLF-NPs Free bLF
AIC R2 AIC R2
Zero Order 94.76 0.84 115.87 0.64
First Order 94.33 0.84 93.67 0.94
Higuchi 77.93 0.96 104.86 0.86
Hyperbola 89.26 0.90 90.60 0.96
Korsmeyer–Peppas n = 0.014 n = 0.022
67.83 0.98 93.91 0.94
Ex vivo corneal permeation of bLF-LIP and free bLF were performed to study their
behaviour and compare different permeation parameters (Figure 4a). Permeation parame-
ters were obtained by plotting the cumulative bLF permeated versus time, determining
the x-intercept by linear regression analysis (Figure 4b) [66]. Table 4 shows that bLF-LIP
formulation presents statistically significant differences (p < 0.05) against free bLF in all
examined permeation parameters. According to the steady-state flux (J) value is twice
higher in bLF-LIP, therefore bLF from LIPs infused the cornea faster than free bLF. All
permeation parameters follow similar ratios, with the permeability coefficient (Kp) and the
quantity permeated at 24 h (Q24) greater in bLF-LIP than free bLF. Otherwise, the opposite
ratio is observed in the case of QR, being twice longer the bLF quantity retained in the
cornea from free bLF sample. Owing to their high lipophilicity, the epithelium layer of
the cornea, composed of lipid, favoured the release of bLF-LIP and prevents the entry of
hydrophilic substances, such as free bLF solution, thus retaining a significant part of the
protein in the cornea [67]. Furthermore, particles below 100 nm, particles with deformable
nature and positively charged liposomes could potentially facilitate their permeability
and absorption through the corneal membrane, leading to an enhance in all pharmacoki-
netic parameters [31,47]. Therefore, bLF-LIP may efficiently release bLF to the specified
area by delivering bLF slowly across the corneal tissue, which would be helpful for the
management of DED and the derived ocular inflammation.
Figure 4. Biopharmaceutical behaviour. (a) In vitro release profile of bLF-LIP (Korsmeyer–Peppas equation) against free bLF
(hyperbola equation). (b) Ex vivo corneal permeation profile of bLF-LIP compared with free bLF and permeation parameters.
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Table 4. Pharmacokinetic parameters adjusted to linear regression of the ex vivo corneal permeation
of bLF-LIP against bLF.
Parameters Free bLF bLF-LIP
J (µg·h−1·cm−2) 171.79 ± 9.83 317.50 ± 67.84 *
Kp · 103 (cm·h−1) 8.59 ± 0.49 15.88 ± 3.39 *
Q24 (µg) 2635.83 ± 151.49 4874.52 ± 1042.71 *
QR (µg·g−1·cm−2) 1.12 ± 0.01 0.55 ± 0.02 **
Statistical significance: * p < 0.05, ** p < 0.0001. J, steady-state flux; Kp, permeability coefficient; Q24, permeated
amount at 24 h; QR, retained amount.
3.6. Cytotoxicity
To settle liposomes ocular administration suitability, in vitro MTT cytotoxicity assay
was evaluated in HCE-2 cells (Figure 5). Results showed that after 24 h incubation both
bLF-LIP and free bLF did not cause relevant cytotoxic effects. Cell viability was higher
than 80% at all concentrations tested.
LF is one of the most abundant components in the healthy tear fluid, representing
20–30% of the total proteins, varying between 0.63–2.9 mg·mL−1, depending on gender
and age [68,69]. The basal tear flow (1 µL·min−1) is considerably increased upon acute
stimulation, the expression of LF is upregulated to inhibit the production of inflammatory
cytokines [18]. Moreover, LF contributes to antimicrobial activity via inhibiting the growth
of bacteria and mitigates oxidative stress via iron retention mechanism [5,16]. However,
current research has proved that these activities are inactive in DED patients [70]. It is
due to the fact that there is a reduced LF amount at ocular level, since tear volumes have
positive correlation with LF concentration [18]. Hence bLF-LIP could provide a sustained
release of protein and improve its bioavailability, for cases in which LF tear concentration
is compromised.
Regarding other formulation components, it has been reported that lipoid s75 (soy-
bean phospholipids with 70% phosphatidylcholine) is non-immunogenic, biocompatible,
biodegradable and a safe substance used for the development of lipid vehicles for deliver-
ing pharmacological substances with a broad range of solubilities at ocular level [62,71].
HA is widely used in the management of DED. Is a naturally occurring, endogenous,
glycosaminoglycan polymer present in various tissue fluids in human body, mainly in the
extracellular matrix [72]. In particular, high molecular weight HA (>1000 kDa) was reported
to have some immunosuppressive, antioxidant, anti-inflammatory, anti-angiogenic effect,
and wound repair capacity [73].
These outcomes verify the biocompatibility of the developed bLF-LIP with corneal
cells, matching with the generally recognized as safe (GRAS) designation of the formulation
components [71].
Figure 5. Effect of bLF-LIP on the viability of HCE-2 cells. The 100% cell viability corresponds with
the average of MTT reduction values of untreated cells.
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3.7. Ocular Tolerance
In vitro ocular tolerance was studied by HET-CAM test. bLF-LIP and free bLF were
proved to verify the potential instant irritation response in the CAM of 3 eggs. The addition
of free bLF solution or bLF-LIP did not reveal any sign of damage or vascular alteration.
Likewise, negative control (0.9% NaCl) did not produce any response over the time tested.
In contrast, the addition of positive control (1M NaOH) generated a severe vasoconstriction
and haemorrhage [74]. As shown in Figure 6, the suitability for ocular administration
is confirmed. The outcome showed that, at the ocular level, bLF-LIP are classified as a
non-irritating substance (Table 5). These results agree to those obtained by in vitro HCE-2
cytotoxicity assays.
Figure 6. HET-CAM test assessed with different formulations: (a) bLF-LIP; (b) free bLF and (c)
positive control.





bLF-LIP 0.07 ± 0.00 0.00 ± 0.00 Non-irritant
Free bLF (20 mg·mL−1) 0.07 ± 0.00 0.00 ± 0.00 Non-irritant
In vivo ocular tolerance Draize test or primary irritation test was assessed to verify the
irritation potential of the optimized liposomes formulation [75]. Rabbit model is commonly
chosen to perform these experiments because its ocular physiology is well known and
implies easy manipulation. Moreover, rabbit eye is usually more susceptible to irritation
than the human eye [76]. Due to the high sensibility of the ocular surface, it was essential
to check possible irritating effects or ocular damage caused [26].
The in vivo test was assessed considering taking into account that each of the formu-
lation compounds was safe and biocompatible, based on the previously performed in vitro
HET-CAM test and analysed by other authors [48,77].
Results showed no signs of redness, ocular inflammation, or increased tear produc-
tion following instillation of bLF-LIP, being the total score for each rabbit zero (Table 5).
Therefore, bLF-LIP could be classified as non-irritant substance.
3.8. Therapeutic Efficacy against Dry Eye Disease
Aiming to verify the therapeutic efficacy of the developed bLF-LIP in the treatment of
dry eye, the Schirmer’s test was carried out. A severe decrease in the aqueous tear secretion
was achieved after the application of benzalkonium chloride for 2 weeks. Figure 7 showed a
considerable difference between the tear volume secreted by the dry eye of positive control
and by the group treated with liposomes. There were statistically significant differences
on days 0 and 5 in bLF-LIP group, being 6.25-fold higher after 5 days of treatment, and
4.5-fold greater than the eye treated with physiological saline. These results matched with
the result obtained by other authors. One of these studies reported an ameliorated dry eye
symptoms and tear film stability in patients supplemented with oral LF [78]. Furthermore,
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these results are supported by other authors that studied the ocular instillation of LF in a
rabbit dry eye model, resulting in a restoration of corneal epithelial integrity, suggesting
its potential use for treating DED [77]. In the case of the developed bLF-LIP formulation,
improved drug pharmacokinetics and pharmacodynamics were observed thanks to its
encapsulation within biocompatible lipidic nanosystem.
Figure 7. Schirmer’s test results. Values are expressed as mean ± SD; * p < 0.05 significantly higher
than the secreted tear by non-treated with bLF-LIP eye for 5 days.
3.9. Anti-Inflammatory Efficacy
3.9.1. In Vitro Assays: IL-8 and TNF-α Determination
There is evidence that in the dry eye syndrome and chronic inflammation-associated,
tears present overexpression of different inflammatory mediators, specially IL-8 and TNF-α
cytokines [79]. Hence, the in vitro cytokines determination was carried out in HCE-2
cells to assess the ability of bLF-LIP to inhibit the inflammatory response caused by LPS
(Figure 8a,b) [80].
Various authors have studied the influence of DED on the presence of different in-
flammation markers at ocular level. It has been reported that there is a significant increase
of inflammation, doubling the concentration of IL-8 in patients with DED compared with
healthy controls [2,81]. This high concentration of IL-8 at the tear level leads to the migration
of different immune cells towards the eye, triggering the aggravation of the ocular inflam-
mation symptoms present in the disease [15]. At the same time, higher tear concentration
of another inflammatory cytokine, TNF-α, had been detected, keeping the inflammatory
environment in patients with different ophthalmopathies-associated [79,81,82].
In Figure 8 it can be observed that the highest levels of cytokines induced by LPS
were obtained in the absence of bLF-LIP (positive control). Administration of bLF-LIP
considerably diminished the expression of IL-8 and TNF-α, reaching similar levels to those
obtained with free bLF (p < 0.05). This fact indicated that an anti-inflammatory effect was
achieved with the administration of bLF-LIP in corneal cells.
The findings are in accordance with what has been described for LF, which has the
capacity to modulate the expression of various cytokines through different mechanisms [77].
Including the interaction with cell surface receptors involved in the inflammatory response,
by binding to CD14 receptor, thus diminishing NF-κB-induced transcription of various
genes encoding inflammatory mediators [13,21,83]. Regarding to its iron-chelating ability,
LF can manage the oxidative burst produced by neutrophils and macrophages, by oxygen
free radical and hydroxyl scavenging activities, thus mitigating the inflammatory response
and tissue damage caused by ROS [19].
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Figure 8. (a) Quantification of secreted IL-8 proinflammatory cytokine in LPS-stimulated HCE-2 cells; (b) quantification of
secreted TNF-α. Negative control: no treatment; Positive control: LPS. Values are expressed as the mean ± SD; * p < 0.05;
** p < 0.01 significantly lower than LPS-induced cytokine concentration.
3.9.2. In Vivo Assays
In vivo anti-inflammatory efficacy was assayed to confirm the capacity of the lipo-
somes to prevent and treat ocular inflammation through two different tests.
In vivo inflammatory prevention test showed significant differences between the
degree of inflammation treated with bLF formulations or physiological serum during all
the timepoints tested. Nevertheless, eyes treated with bLF-LIP presented a faster swelling
reduction rather than free bLF, mainly owing to tear clearance in case of free bLF and the
improved ocular surface adherence of liposomes, thus presenting longer residence time
in the cornea [26]. bLF-LIP exhibited significant differences regarding positive control
over the time. Thus, bLF-LIP exhibited a preventive effect of inflammation caused by the
sustained release of bLF to the corneal cells (Figure 9a).
In addition, the in vivo inflammation treatment was assessed. Liposomes and free bLF
were applied after 30 min of SA exposure, and the degree of inflammation was quantified.
Figure 9b revealed that the degree of inflammation was significantly reduced after the
first hour post-administration of bLF-LIP. This fact confirms its controlled bLF release from
liposomes, providing a longer anti-inflammatory activity and enhancing its bioavailability.
The presence of a cationic surface charge in the lipidic nanocarrier, may increase the
residence time by interaction with the negatively charged corneal epithelium and the
mucins from tears fluid and conjunctiva [56]. Moreover, statistically significant differences
were observed between the positive inflammation control and the group treated with
free bLF, displaying its anti-inflammatory activity [19]. After 90 min of contact, both bLF
formulations were effective in treating inflammation symptoms. However, a greater and
faster reduction was observed in the case of bLF-LIP during the assay. Hence, it can be
concluded that the controlled release system based on bLF-LIP has ocular anti-inflammatory
activity, both for prevention level and inflammation treatment.
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Figure 9. (a) Ocular inflammation prevention. (b) Ocular inflammation treatment test. Values are expressed as mean ±
SD; * p < 0.05, ** p < 0.01 and *** p < 0.001 and **** p < 0.0001 significantly lower than the inflammatory effect induced by
SA; $ p < 0.05, $$ p < 0.01 and $$$ p < 0.001 and $$$$ p <0.0001 significantly lower than the inflammatory effect induced by
free bLF.
4. Conclusions
In summary, a novel nanotechnological tool has been developed for the management
of DED and its ocular complications. It is based on the encapsulation of bLF, an anti-
inflammatory and antioxidant high molecular weight protein, into hyaluronic acid coated
liposomes. This nanosystem has been proven to be physically stable with a prolonged
bLF release as well as high corneal permeability, thus improving biopharmaceutical bLF
behaviour. In addition, in vitro and in vivo tests corroborate that the developed formula-
tion is biocompatible without any sign of ocular irritation or cytotoxicity. Furthermore,
bLF-LIP exert the ability to revert DED symptoms by restoring physiological tear levels.
At the same time, bLF-LIP were able to decrease inflammation both in vitro and in vivo.
Hence, hyaluronic acid coated bLF-loaded liposomes constitute a suitable system to treat
and prevent DED and ocular inflammation.
5. Patents
Liposomes described in this work have been patented under the reference EP 3603621
A1 and this patent has recently been extended to the US under the reference US 10,835,494 B2.
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Appendix A
Table A1. Rating scale to evaluate the degree of ocular irritation (Draize test).
Structure Injury Evaluation Score
CORNEA
(A) Degree of cloudiness or opacity
Corneal score:
A × B × 5
Maximum score:
80







-A quarter or less 1
-More than a quarter but without means 2
-More than three quarters up a whole plane 3
-More than half but less than three quarters 4
IRIS





-Deep folds, congestion, swelling, moderate
circumcorneal injection 1









-Some clearly injected vessels 1
-Diffuse redness 2
-Big diffuse redness 3
(B) Chemosis or Inflammation
-None 0
-Some 1
-Marked with partial disorder of the eyelids 2




-Any amount anomalous 1
-Wetting and eyelid hairs 2
-Periocular wetting 3
Calculation of the Ocular Irritation Index OII Classification
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